
cAMP反应元件结合蛋白/Bcl-2在小儿急性白血病骨髓细胞中的表达及意义
文川, 马夫天, 万伍卿
中国当代儿科杂志 ›› 2010, Vol. 12 ›› Issue (3) : 177-180.
cAMP反应元件结合蛋白/Bcl-2在小儿急性白血病骨髓细胞中的表达及意义
Expression of CREB/Bcl-2 in bone marrow mononuclear cells of children with acute leukemia
cAMP反应元件结合蛋白 / Bcl-2 / 急性白血病 / 儿童
Cyclic-AMP response binding protein / Bcl-2 / Acute leukemia / Child
[1]李晟,陈子兴,王玮,芩建农,傅建新,姚利. CXCR4在急性白血病细胞中的表达及其对髓外浸润的意义[J]. 中华血液学杂志,2004, 25(7):405-408.
[2]顾龙君. 中华医学会儿科学分会血液学组.儿童急性淋巴细胞白血病诊疗建议:第三次修订草案[J]. 中华儿科杂志, 2006, 44(5):392-395.
[3]Shankar DB, Cheng JC, Sakamoto KM. Role of cyclic AMP response element binding protein in human leukemias[J]. Cancer, 2005, 104(9):1819-1824.
[4]Siu YT, Jin DY. CREB—a real culprit in oncogenesis[J]. FEBS J, 2007, 274(13):3224-3232.
[5]Cheng JC, Esparza S, Sandoval S,Shankar D, Fu C, Sakamoto KM. Potential role of CREB as a prognostic marker in acute myeloid leukemia[J]. Future Oncol, 2007, 3(4):475-480.
[6]Orelio C, Dzierzak E. Bcl-2 expression and apoptosis in the regulation of hematopoietic stem cells[J]. Leuk Lymphoma, 2007, 48(1):16-24.
[7]Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy[J]. Cell Death Differ, 2009, 16(3):360-367.
[8]Tabe Y. Molecular diagnosis of and molecular targeting therapy for leukemia[J]. Rinsho Byori, 2009, 57(2):137-145.
[9]Fulda S. Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia[J]. Br J Haematol, 2009, 145(4):441-454.
[10]Schuler D, Szende B. Apoptosis in acute leukemia[J]. Leuk Res, 2004, 28(7):661-666.
[11]Crans-Vargas HN, Landaw EM, Bhatia S, Sandusky G, Moore TB, Sakamoto KM. Expression of cyclic adenosine monophosphate responseelement binding protein in acute leukemia[J]. Blood, 2002, 99(7):2617-2619.
[12]Pigazzi M, Ricotti E, Germano G, Faggian D, Aricò M, Basso G. cAMP response element binding protein (CREB) overexpression CREB has been described as critical for leukemia progression[J]. Haematologica, 2007, 92(10):1435-1437.
[13]Moon JH, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW, et al. BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients[J]. Leuk Res, 2010, 34(2):166-172.
[14]Zhang CY, Wu YL, Boxer LM. Impaired proliferation and survival of activated B cells in transgenic mice that express a dominant-negative cAMP-response element-binding protein transcription factor in B cells[J]. J Biol Chem, 2002, 277(50):48359-48365.
[15]Joo EK, Broxmeyer HE, Kwon HJ, Kang HB, Kim JS, Lim JS, et al. Enhancement of cell survival by stromal cell-derived factor-1/CXCL12 involves activation of CREB and induction of Mcl-1 and c-Fos in factor-dependent human cell line MO7e[J]. Stem Cells Dev, 2004, 13(5):563-570.
[16]Swart JM, Bergeron DM, Chiles TC. Identification of a membrane Ig-induced p38 mitogen-activated protein kinase module that regulate cAMP response element binding protein phosphorylation and transcriptional activation in CH31 B cell lymphomas[J]. J Immunol, 2000, 164(5):2311-2319.
[17]Aucoin R, Reiland J, Roy M, Marchetti D. Dominant-negative CREB inhibits heparanase functionality and melanoma cell invasion[J]. J Cell Biochem, 2004, 93(2):215-223.
[18]赵晓庆,李根山,郭稳捷,李艳芝. bcl-2和bax蛋白在儿童急性白血病表达及临床意义[J]. 中国当代儿科杂志, 1999, 1(4):193-195.
[19]Pino MS, Nawrocki ST, Cognett F, Abruzzese JL, Xiong HQ, McConkey DJ. Prostaglandin E2 drives cyelooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells[J]. Cancer Biol Ther, 2005, 4(11):1263-1269.
[20]Sachs L, Lotem J. Contro l of programmed cell death in normal and leukemic cells: new implications for therapy[J]. Blood, 1993, 82 (1):15-21.